US2002082425A1PendingUtilityA1
Aryl and heteroaryl fused aminoalkyl-imidazole derivatives
Est. expiryApr 2, 2019(expired)· nominal 20-yr term from priority
G01N 2333/72C07D 235/14C07D 471/04
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, and D are variables defined herein. Such compounds useful in treatment of obesity and diabetes. The invention also provides labeled probes for the localization of cellular receptors that are involved in the modulation of blood glucose levels.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of the formula:
or pharmaceutically acceptable non-toxic salts thereof wherein:
R 7 represents H, or C 1 -C 6 alkyl;
when R 7 is H, R 1 represents 2-, 3-, or 4-picolyl or benzyl, each of which is optionally mono-, di-, or trisubstituted independently with
halogen, nitro, trifluoromethyl, cyano, hydroxyl, C 1 -C 6 alkoxy, or C 1 -C 6 alkyl;
amino, mono or di(C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkyl, or mono- or di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, or mono- or di (C 1 -C 6 ) alkylamino (C 1 -C 6 ) alkoxy;
—O(CH 2 ) n CO 2 R 8 where n is 1,2,3,4, NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or C 1 -C 6 alkyl; or
NR 8 R 9 forms a 5-, 6- or 7-membered heterocycloalkyl ring;
SO 2 R 8 , NHSO 2 R 8 , SO 2 NHR 8 , SO 2 NHCOR 8 , CONHSO 2 R 8 where R 8 is as defined above;
O(CH 2 )n—G where n=1,2,3 or 4 and G represents SO 2 R 8 , NHSO 2 R 8 , SO 2 NHR 8 , SO 2 NHCOR 8 , CONHSO 2 R 8 , where R 8 is as defined above; or
tetrazole, triazole, imidazole, thiazole, oxazole, thiophene, or pyridyl;
when R 7 represents C 1 -C 6 alkyl, R 1 represents C 1 -C 6 alkyl, cyclopentyl, or cyclopropylmethyl;
R 2 represents
hydroxy;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, each of which is optionally substituted with amino or mono- or di(C 1 -C 6 )alkylamino, C 5 -C 7 cycloalkylamino or C 1 -C 7 cycloalkoxy; or
O(CH 2 ) n CO 2 R 8 where n=1,2,3 or 4, NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or C 1 -C 6 alkyl; or
NR 8 R 9 forms 5-, 6-, or 7-membered heterocyclic ring;
R 3 represents C 1 -C 6 alkyl;
R 4 represents C 1 -C 6 alkoxy; or
R 4 represents methyl when R 1 and R 7 are lower alkyl;
R 5 and R 6 are the same or different and represent hydrogen or halogen;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, the alkyl portion of each being optionally substituted with amino, mono- or di(C 1 -C 6 ) alkylamino, or a C 5 -C 7 heterocycloalkyl group where the heteroatom is nitrogen and the nitrogen is attached to the parent alkyl portion;
O(CH 2 ) n CO 2 R 8 where n=1,2,3,4, NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or straight or branched chain lower alkyl having 1-6 carbon atoms;
NR 8 R 9 forms a 5-, 6- or 7-membered heterocyclic ring;
X represents a bond, CH 2 O, or CH═CH; and
A, B, C, and D are the same or different and represent CH or N with the proviso that not more than two of A, B, C and D represent N.
2 . A compound of the formula
where
R 7 is C 1 -C 6 alkyl;
R 1 represents benzyl optionally mono-, di-, or trisubstituted independently with halogen, nitro, trifluoromethyl, cyano, hydroxyl, C 1 -C 6 alkoxy, or C 1 -C 6 alkyl; or
amino, mono or di(C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkyl, or mono- or di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, or mono- or di (C 1 -C 6 ) alkylamino (C 1 -C 6 ) alkoxy;
R 2 represents
hydroxy;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, each of which is optionally substituted with amino or mono- or di(C 1 -C 6 )alkylamino, C 5 -C 7 cycloalkylamino or C 5 -C 7 cycloalkoxy; or
O(CH 2 ) n CO 2 R 8 where n=1,2,3 or 4, NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or C 1 -C 6 alkyl; or
NR 8 R 9 forms 5-, 6-, or 7-membered heterocyclic ring;
R 3 represents C 1 -C 6 alkyl;
R 4 represents C 1 -C 6 alkoxy; or
R 5 and R 6 are the same or different and represent hydrogen or halogen;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, the alkyl portion of each being optionally substituted with amino, mono- or di(C 1 -C 6 ) alkylamino, or a C 5 -C 7 heterocycloalkyl group where the heteroatom is nitrogen and the nitrogen is attached to the parent alkyl portion; and
X represents a bond or CH 2 O.
3 . A compound according to claim 2 , wherein one of R 5 and R 6 is hydrogen.
4 . A compound according to claim 2 , wherein R 4 is methoxy, one of R 5 and R 6 is hydrogen, and the other of R 5 and R 6 is alkoxy.
5 . A compound according to claim 2 , wherein R 7 is C 4 -C 6 alkyl.
6 . A compound according to claim 5 , wherein X is a bond.
7 . A compound according to claim 2 , wherein R 1 is benzyl monosubstituted in the ortho position.
8 . A compound according to claim 7 , wherein R 7 is C 4 -C 6 alkyl and X is a bond.
9 . A compound of the formula:
wherein:
R 7 represents C 1 -C 6 alkyl;
R 1 represents C 1 -C 6 alkyl, cyclopentyl, or cyclopropylmethyl;
R 2 represents
hydroxy;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, each of which is optionally substituted with amino or mono- or di(C 1 -C 6 )alkylamino, C 5 -C 7 cycloalkylamino or C 5 -C 7 cycloalkoxy; or
O(CH 2 ) n CO 2 R 8 where n=1, 2, 3 or 4 NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or C 1 -C 6 alkyl; or
NR 8 R 9 forms 5-, 6-, or 7-membered heterocyclic ring;
R 3 represents C 1 -C 6 alkyl;
R 4 represents C 1 -C 6 alkoxy; or
R 4 represents methyl when R 1 and R 7 are lower alkyl;
R 5 and R 6 are the same or different and represent hydrogen or halogen;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, the alkyl portion of each being optionally substituted with amino, mono- or di(C 1 -C 6 ) alkylamino, or a C 1 -C 7 heterocycloalkyl group where the heteroatom is nitrogen and the nitrogen is attached to the parent alkyl portion;
O(CH 2 ) n CO 2 R 8 where n=1, 2, 3 or 4 NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or straight or branched chain lower alkyl having 1-6 carbon atoms;
NR 8 R 9 forms a 5-, 6- or 7-membered heterocyclic ring;
X represents a bond or CH 2 O.
10 . A compound according to claim 9 wherein R 3 and R 7 are methyl.
11 . A compound according to claim 9 wherein R 1 is propyl or cyclopropylmethyl.
12 . A compound according to claim 9 wherein R 1 is cyclopentyl.
13 . A compound according to claim 9 wherein X is CH 2 O.
14 . A compound according to claim 13 , wherein R 1 is propyl or cyclopropylmethyl.
15 . A compound according to claim 9 , wherein R 1 is propyl or cyclopropylmethyl and one of R 5 and R 6 is hydrogen.
16 . A compound according to claim 9 , wherein R 1 is propyl, R 4 is methoxy or methyl, one of R 5 and R 6 is hydrogen, and the other of R 5 and R 6 is alkoxy.
17 . A compound of the formula:
wherein:
R 7 represents C 1 -C 6 alkyl;
R 1 represents C 1 -C 6 alkyl, cyclopentyl, or cyclopropylmethyl;
R 2 represents
hydroxy;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, each of which is optionally substituted with amino or mono- or di(C 1 -C 6 )alkylamino, C 5 -C 7 cycloalkylamino or C 5 -C 7 cycloalkoxy; or
O(CH 2 ) n CO 2 R 8 where n=1, 2, 3 or 4 NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or C 1 -C 6 alkyl; or
NR 8 R 9 forms 5-, 6-, or 7-membered heterocyclic ring;
R 3 represents C 1 -C 6 alkyl;
R 4 represents C 1 -C 6 alkoxy; or
R 4 represents methyl when R 1 and R 7 are lower alkyl;
R 5 and R 6 are the same or different and represent hydrogen or halogen;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, the alkyl portion of each being optionally substituted with amino, mono- or di(C 1 -C 6 ) alkylamino, or a C 5 -C 7 heterocycloalkyl group where the heteroatom is nitrogen and the nitrogen is attached to the parent alkyl portion;
O(CH 2 ) n CO 2 R 8 where n=1,2,3 or 4, NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or straight or branched chain lower alkyl having 1-6 carbon atoms;
NR 8 R 9 forms a 5-, 6- or 7-membered heterocyclic ring;
X represents a bond or CH 2 O.
18 . A compound according to claim 17 wherein R 3 and R 7 are methyl.
19 . A compound according to claim 17 wherein R 1 is propyl or cyclopropylmethyl.
20 . A compound according to claim 17 wherein R 1 is cyclopentyl.
21 . A compound according to claim 17 wherein X is CH 2 O.
22 . A compound according to claim 21 , wherein R 1 is propyl or cyclopropylmethyl.
23 . A compound according to claim 17 , wherein R 1 is propyl or cyclopropylmethyl and one of R 5 and R 6 is hydrogen.
24 . A compound according to claim 17 , wherein R 1 is propyl, R 4 is methoxy or methyl, one of R 5 and R 6 is hydrogen, and the other of R 5 and R 6 is alkoxy.
25 . A compound of the formula
where
R 7 is hydrogen or C 1 -C 6 alkyl;
R 1 represents benzyl optionally mono-, di-, or trisubstituted independently with
halogen, nitro, trifluoromethyl, cyano, hydroxyl, C 1 -C 6 alkoxy, or C 1 -C 6 alkyl; or
amino, mono or di(C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkyl, or mono- or di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, or mono- or di (C 1 -C 6 ) alkylamino (C 1 -C 6 ) alkoxy;
R 2 represents
hydroxy;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, each of which is optionally substituted with amino or mono- or di(C 1 -C 6 )alkylamino, C 5 -C 7 cycloalkylamino or C 1 -C 7 cycloalkoxy; or
O(CH 2 ) n CO 2 R 8 where n=1,2,3 or 4, NR 8 COR 9 , COR 8 , CONR 8 R 9 or CO 2 R 8 where R 8 and R 9 are the same or different and represent hydrogen or C 1 -C 6 alkyl; or
NR 8 R 9 forms 5-, 6-, or 7-membered heterocyclic ring;
R 3 represents C 1 -C 6 alkyl;
R 4 represents C 1 -C 6 alkoxy; or
R 5 and R 6 are the same or different and represent hydrogen or halogen;
C 1 -C 6 alkyl or C 1 -C 6 alkoxy, the alkyl portion of each being optionally substituted with amino, mono- or di(C 1 -C 6 ) alkylamino, or a C 5 -C 7 heterocycloalkyl group where the heteroatom is nitrogen and the nitrogen is attached to the parent alkyl portion; and
X represents a bond or CH 2 O.
26 . A compound according to claim 25 , wherein one of R 5 and R 6 is hydrogen.
27 . A compound according to claim 25 , wherein R 4 is methoxy, one of R 5 and R 6 is hydrogen, and the other of R 5 and R 6 is alkoxy.
28 . A compound according to claim 25 , wherein R 7 is C 4 -C 6 alkyl.
29 . A compound according to claim 25 , wherein X is a bond.
30 . A compound according to claim 25 , wherein R 1 is benzyl monosubstituted in the ortho position.
31 . A compound according to claim 30 , wherein R 7 is C 4 -C 6 alkyl and X is a bond.
32 . A compound according to claim 1 , which is ((2,4-dimethoxyphenyl)-N-(3-methylbutyl)-N-({1-[(2-methylphenyl)methyl]benzimidazol-2-yl}methyl)carboxamide
33 . A compound according to claim 1 , which is 2-(2,3-dimethylphenoxy)-N-methyl-N- [(1-propylbenzimidazol-2-yl) ethyl]acetamide.
34 . A compound according to claim 1 , which is 2-(2,3-dimethylphenoxy)-N-{[1-(cyclopropylmethyl)benzimidazol-2-yl]ethyl}-N-methylacetamide.
35 . A compound according to claim 1 , which is (2,4-dimethoxyphenyl)-N-({1-[(2-chlorophenyl)methyl]benzimidazol-2-yl}methyl)-N-(3-methylbutyl)carboxamide.
36 . A compound according to claim 1 , which is (2,4-dimethoxyphenyl)-N-(3-methylbutyl)-N-({3-[(2-methylphenyl)methyl]imidazolo[5,4-b],pyridin-2-yl}methyl)carboxamide.
37 . A compound according to claim 1 , which is 2-(2,3-dimethylphenoxy)-N-methyl-N-[(-popylimidazolo[5,4-b]pyridin -2-yl) ethyl]acetamide.
38 . A compound according to claim 1 , which is 2-(2,3-dimethylphenoxy)-N-{[1-(cyclopentyl)-6-chlorobenzimidazol-2-yl]ethyl}-N-methylacetamide
39 . A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier or excipient.
40 . A method of treating diabetes, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
41 . A method of treating obesity or eating disorders, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
42 . The use of a compound of claim 1 for the manufacture of a medicament for the treatment of diabetes or obesity.
43 . A process for the preparation of a compound of claim 1 .
44 . A method for localizing receptors in a tissue sample comprising:
contacting the sample with a detectably-labeled compound of claim 1 under conditions that permit binding of the compound to the receptors, washing the sample to remove unbound compound, and detecting the bound compound.
45 . The method of claim 44 , wherein the receptors modulate blood glucose levels.
46 . The method of claim 44 , wherein the receptors are GLP-1 receptors.
47 . A packaged pharmaceutical composition comprising the pharmaceutical composition of claim 39 in a container and instructions for using the composition to treat a patient suffering from a disorder responsive to modulation of blood glucose levels.
48 . The packaged pharmaceutical composition of claim 47 , wherein said patient is suffering from obesity or diabetes.Join the waitlist — get patent alerts
Track US2002082425A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.